Cytokinetics (CYTK) Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum summary

Company history and strategic vision

• Founded in 1997, initially focused on oncology and antifungal, later pivoted to cardiovascular and muscle biology based on scientific insights.

• Vision 2030 aims for two approved therapies, three indications, and 10 NMEs by 2030, with commercial presence in over 15 countries.

• Emphasis on maintaining internal control in key markets (U.S. and Europe) while partnering in select territories like China and Japan.

• Five pillars include commercial growth, global reach, leadership in muscle biology, patient impact, and strong internal culture.

• Business development focuses on early-stage assets and novel modalities, with a shift from out-licensing to in-licensing technologies.

Product portfolio and clinical pipeline

• MYQORZO, a cardiac myosin inhibitor, launched in the U.S. and Germany for obstructive HCM, with expansion planned in Europe and other regions.

• MYQORZO prescriptions tripled from Q1 to Q2, with a goal to reach 50% of new prescriptions by year-end; strong clinical data and ease of use drive adoption.

• ACACIA data supports potential approval for non-obstructive HCM, which could double the addressable patient population.

• Omecamtiv mecarbil, a cardiac myosin activator, is in phase III for HFrEF, targeting patients with high unmet need; readout expected around 2028.

• Ulacamten is in phase II for HFpEF, focusing on a specific subpopulation; initial results expected in 2027, with phase III planning underway.

Competitive positioning and market expansion

• MYQORZO differentiates through broad clinical data, REMS program, and potential to be the only CMI approved for both obstructive and non-obstructive HCM.

• Expansion into non-obstructive HCM and additional territories is a key growth driver.

• Omecamtiv offers a unique mechanism as an activator, addressing contractility without adverse effects seen in older therapies.

• The company aims to cover the full spectrum of heart failure with its three lead programs, leveraging overlap in prescriber base and clinical infrastructure.

• Ongoing investment in scientific leadership and data generation supports prescriber confidence and market adoption.